MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ngan, V. K.
Right arrow Articles by Jordan, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ngan, V. K.
Right arrow Articles by Jordan, M. A.

Vol. 60, Issue 1, 225-232, July 2001

Mechanism of Mitotic Block and Inhibition of Cell Proliferation by the Semisynthetic Vinca Alkaloids Vinorelbine and Its Newer Derivative Vinflunine

Vivian K. Ngan, Krista Bellman, Bridget T. Hill, Leslie Wilson, and Mary Ann Jordan

Department of Molecular, Cellular, and Developmental Biology and Neuroscience Research Institute, University of California, Santa Barbara, California (V.K.N., K.B., L.W., M.A.J.) and Division de Cancerologie Experimentale, Centre de Recherche Pierre Fabre, Castres, France (B.T.H.)

The two second-generation Vinca alkaloids, vinorelbine and vinflunine, affect microtubule dynamics very differently from vinblastine, a first generation Vinca alkaloid. For example, vinblastine strongly suppresses the rate and extent of microtubule shortening in vitro, whereas vinorelbine and vinflunine suppress the rate and extent of microtubule growing events. We asked whether these differences result in differences in mitotic spindle organization that might be responsible for the superior antitumor activities of the two second-generation Vinca alkaloids. IC50 values for inhibition of HeLa cell proliferation for vinflunine, vinorelbine, and vinblastine were 18, 1.25, and 0.45 nM, respectively, similar to the concentrations that induced mitotic block at the metaphase/anaphase transition (38, 3.8, and 1.1 nM, respectively), indicating that mitotic block is a major contributor to antiproliferative action for all three drugs. Mitotically blocked cells exhibited aberrant spindles, consistent with induction of block by suppression of microtubule dynamics. Despite differences in their actions on individual dynamic instability parameters, morphologically detectable differences in spindle effects among the three drugs were minimal, indicating that overall suppression of dynamics may be more important in blocking mitosis than specific effects on growth or shortening. We also found that the peak intracellular drug concentration at the mitotic IC50 value was highest for vinflunine (4.2 ± 0.2 µM), intermediate for vinorelbine (1.3 ± 0.1 µM), and more than 10-fold lower for vinblastine (130 ± 7 nM), suggesting that intracellular binding reservoir(s) may be partially responsible for vinflunine's high efficacy and minimal side effects.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. Bennouna, J.-P. Delord, M. Campone, and L. Nguyen
Vinflunine: A New Microtubule Inhibitor Agent
Clin. Cancer Res., March 15, 2008; 14(6): 1625 - 1632.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-S. Kim, Y.-C. Lee, H.-T. Nam, G. Li, E.-J. Yun, K.-S. Song, K.-S. Seo, J.-H. Park, J.-W. Ahn, O. Zee, et al.
Apicularen A Induces Cell Death through Fas Ligand Up-Regulation and Microtubule Disruption by Tubulin Down-Regulation in HM7 Human Colon Cancer Cells
Clin. Cancer Res., November 1, 2007; 13(21): 6509 - 6517.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M.-A. Esteve, M. Carre, V. Bourgarel-Rey, A. Kruczynski, G. Raspaglio, C. Ferlini, and D. Braguer
Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine.
Mol. Cancer Ther., November 1, 2006; 5(11): 2824 - 2833.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Pourroy, S. Honore, E. Pasquier, V. Bourgarel-Rey, A. Kruczynski, C. Briand, and D. Braguer
Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.
Cancer Res., March 15, 2006; 66(6): 3256 - 3263.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Johansen, J. Kuttesch, W. A. Bleyer, M. Krailo, M. Ames, and T. Madden
Phase I Evaluation of Oral and Intravenous Vinorelbine in Pediatric Cancer Patients: A Report from the Children's Oncology Group
Clin. Cancer Res., January 15, 2006; 12(2): 516 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. A. Jordan, K. Kamath, T. Manna, T. Okouneva, H. P. Miller, C. Davis, B. A. Littlefield, and L. Wilson
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
Mol. Cancer Ther., July 1, 2005; 4(7): 1086 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Moroni, V. Soldatenkov, L. Zhang, Y. Zhang, G. Stoica, E. Gehan, B. Rashidi, B. Singh, M. Ozdemirli, and S. C. Mueller
Progressive Loss of Syk and Abnormal Proliferation in Breast Cancer Cells
Cancer Res., October 15, 2004; 64(20): 7346 - 7354.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. Pourroy, M. Carre, S. Honore, V. Bourgarel-Rey, A. Kruczynski, C. Briand, and D. Braguer
Low Concentrations of Vinflunine Induce Apoptosis in Human SK-N-SH Neuroblastoma Cells through a Postmitotic G1 Arrest and a Mitochondrial Pathway
Mol. Pharmacol., September 1, 2004; 66(3): 580 - 591.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. A. Lee, M. K. Keutmann, M. L. Dowling, E. Harris, G. Chan, and G. D. Kao
Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells
Mol. Cancer Ther., June 1, 2004; 3(6): 661 - 669.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Honore, K. Kamath, D. Braguer, L. Wilson, C. Briand, and M. A. Jordan
Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation
Mol. Cancer Ther., December 1, 2003; 2(12): 1303 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Okouneva, B. T. Hill, L. Wilson, and M. A. Jordan
The Effects of Vinflunine, Vinorelbine, and Vinblastine on Centromere Dynamics
Mol. Cancer Ther., May 1, 2003; 2(5): 427 - 436.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bennouna, P. Fumoleau, J.-P. Armand, E. Raymond, M. Campone, F.-M. Delgado, C. Puozzo, and M. Marty
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours
Ann. Onc., April 1, 2003; 14(4): 630 - 637.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Vantieghem, Y. Xu, Z. Assefa, J. Piette, J. R. Vandenheede, W. Merlevede, P. A. M. de Witte, and P. Agostinis
Phosphorylation of Bcl-2 in G2/M Phase-arrested Cells following Photodynamic Therapy with Hypericin Involves a CDK1-mediated Signal and Delays the Onset of Apoptosis
J. Biol. Chem., September 27, 2002; 277(40): 37718 - 37731.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Carre, N. Andre, G. Carles, H. Borghi, L. Brichese, C. Briand, and D. Braguer
Tubulin Is an Inherent Component of Mitochondrial Membranes That Interacts with the Voltage-dependent Anion Channel
J. Biol. Chem., September 6, 2002; 277(37): 33664 - 33669.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-G. Chen and S. B. Horwitz
Differential Mitotic Responses to Microtubule-stabilizing and -destabilizing Drugs
Cancer Res., April 1, 2002; 62(7): 1935 - 1938.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
N. Moisoi, M. Erent, S. Whyte, S. Martin, and P. M. Bayley
Calmodulin-containing substructures of the centrosomal matrix released by microtubule perturbation
J. Cell Sci., January 6, 2002; 115(11): 2367 - 2379.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics